AstraZeneca, Pfizer, U.K. Charity’s Joint Lung Cancer Trial Aims To Make Tumor Genetic Testing Routine
This article was originally published in The Pink Sheet Daily
Executive Summary
A pioneering approach to trialing targeted medicines in late-stage NSCLC is being launched throughout Britain, giving researchers unprecedented access to libraries of drugs developed by AstraZeneca and Pfizer, allowing several to be tested at the same time within one trial.